e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New insights into lung disease pathogenesis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Hypoxia associated with increased systemic concentrations of MPO and NE during exacerbations of COPD
Kristina Andelid (Göteborg, Sweden), Kristina Andelid, Pernilla Glader, Shigemi Yoshihara, Anders Andersson, Ann Ekberg-Jansson, Anders Lindén
Source:
International Congress 2015 – New insights into lung disease pathogenesis
Session:
New insights into lung disease pathogenesis
Session type:
Thematic Poster Session
Number:
873
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kristina Andelid (Göteborg, Sweden), Kristina Andelid, Pernilla Glader, Shigemi Yoshihara, Anders Andersson, Ann Ekberg-Jansson, Anders Lindén. Hypoxia associated with increased systemic concentrations of MPO and NE during exacerbations of COPD. Eur Respir J 2015; 46: Suppl. 59, 873
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
COPD exacerbation severity is associated with impaired macrophage phagocytosis of eosinophils
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013
Monitoring catalase activity in COPD exacerbations
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Endothelial dysfunction and systemic inflammation during acute exacerbations of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Inflammatory serum profiles are consistent across independent exacerbations in COPD patients with a history of frequent exacerbations
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Inflammation biomarkers of lung tissue damage in acute exacerbation of COPD patients
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
BNP level in patients with COPD exacerbations
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Altered inflammasome activity in bacterial acute exacerbations of COPD (AECOPD)
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
Increased interferon and decreased NRF2-PPARG signaling is associated with frequent exacerbations in COPD
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Prevalence of exacerbation in COPD patients with chronic bronchitis and association with elevated serum inflammatory biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Assessment of malondialdehyde in the airways during treatment of COPD exacerbations
Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases
Year: 2013
Microparticles in stable and exacerbated COPD patients
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Insulin resistance, lung function and exacerbation rate in chronic obstructive lung disease
Source: International Congress 2015 – Monitoring airway diseases with lung function tests
Year: 2015
Malondialdehyde level in chronic obstructive pulmonary disease exacerbations
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes
Source: International Congress 2018 – Disease exacerbations from a molecular point of view
Year: 2018
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Inflammatory markers and COPD phenotypes as predictors of COPD exacerbations
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013
Presence of progranulin in airway inflammation associated with COPD
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept